| 000 | 01122nam a22001817a 4500 | ||
|---|---|---|---|
| 005 | 20250226152756.0 | ||
| 008 | 250226b ph ||||| |||| 00| 0 eng d | ||
| 022 | _a0360-4039 | ||
| 040 | _cOCT | ||
| 100 | _aDavis Lori | ||
| 240 |
_aNursing 2024 _hNovember 2024 |
||
| 245 |
_aCheckpoint inhibitor therapy: _bImmune-related adverse event management/ _cLori Davis, Mary Beth Casselbury, Sharon Wilson |
||
| 300 |
_aVol. 54 (11) pages 26-34 : _bIllustrations: _c27 cm |
||
| 500 | _aTreatment with immune checkpoint inhibitors for cancer is associated with a high prevalence of multiple immune-related toxicities. Immune-related adverse events (irAEs) can occur anytime during treatment and up to 3 months after treatment. This article discusses checkpoint inhibitor therapy and describes the implementation of a patient education program focused on recognizing immunotherapy irAEs and their toxicities. | ||
| 650 | _aCheckpoint inhibitor therapy, immune-related adverse events (irAEs), immune checkpoint inhibitors (ICIs), immunotherapy, oncology | ||
| 700 | _aCasselbury Mary Beth, Wilson Sharon | ||
| 942 |
_2ddc _cCR _n0 |
||
| 999 |
_c10280 _d10280 |
||